Abbey Blair, PA
Medical · Cleveland, OHNPI 1346344462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,103 of the $23,607 with a category attached, or 85.2%. Incyte Corporation accounts for 99.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $7,500 and has fallen 97.2% since, to $210 in 2025. Among medical clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $342.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$23K
- Seagen Inc.$83
- Stemline Therapeutics Inc.$71
- Genentech USA, Inc.$63
- AstraZeneca$19
What the payments were for
- Speaking & faculty fees$20,10385%
- Travel & lodging$1,1735%
- Food & beverage$2,0329%
- Education$2991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 64 | $23,370 |
| Seagen Inc. | 1 | $83 |
| Stemline Therapeutics Inc. | 1 | $71 |
| Genentech USA, Inc. | 2 | $63 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,607 in reported general payments places this provider in the 95th percentile of 547 medical providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 16 | $192 |
| Levofloxacin | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other medical in Cleveland
- Shirley YeeCleveland$6K
- Allison MartinCleveland$6K
- Claudia LewisCleveland$5K
- Salvatore BordonaroCleveland$5K
- Shannon GhizzoniColumbus$116K
- Susan WhittCanal Winchester$74K
- Christopher FrickLima$46K
- Kodi VealeAkron$43K
- Joana ZulaConcord Twp$23K
- Chelsea AustenColumbus$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.